IPO及再融资上会预告 据交易所官网审核动态信息，本周（9月22日-9月26日）IPO上会审核4家企业，全部获通过，合计拟募资122.33亿元。 本周2家再融资企业上会，全部获通过，合计拟募资8.24亿元。 | 上会日期 数量 | 樂型 | 申报板块 | 公司简称 | 注册地 审核结果 | | 拟募资金额 | 最近一年净利润 | 保荐机构 会计师事务所 律师事务所 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | (万元) | (万元) | | | | | 2025-9-25 | 公开发行 可转债 | 创业板 | 普联软件 | 山东 | 通过 | 24,293.26 | 12,362.43 | 中泰证券 | 致同 | 中伦 | | 2025-9-26 | 公开发行 可转债 | 科创板 | 茂莱光学 | 江苏 | 通过 | 58,125.00 | 3,552.10 | 中争公司 | 公证天业 | 锦天城 | | | | | | | HEADING CONSULTING | | | | | ...

证券代码：688317 证券简称：之江生物 公告编号：2025-054 上海之江生物科技股份有限公司 关于开立募集资金专户并签订募集资金专户监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 上海之江生物科技股份有限公司（以下简称"公司"）首次公开发行股票并在科创板上市的注册申请于 2020年11月27日经中国证券监督管理委员会同意注册（证监许可[2020]3214号《关于同意上海之江生物 科技股份有限公司首次公开发行股票注册的批复》）。公司获准向社会公开发行人民币普通股（A股） 股票4,867.6088万股，每股发行价格人民币43.22元，募集资金合计210,378.05万元，扣除发行费用后， 实际募集资金净额为194,232.16万元。上述募集资金到位情况已经中汇会计师事务所（特殊普通合伙） 审验，并由其出具《验资报告》（中汇会验[2021]第0039号）。 二、 募集资金专户的开立情况及《募集资金专户存储三方监管协议》的签订情况 为规范公司募集资金管理，保护中小投资者的权益，根据《 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 表决结果：9票同意，0票反对，0票弃权。 2024年及2025年1-6月，上生公司营业收入分别为1,197万元、808万元，仅占公司营业收入的0.2%、 0.26%；2024年及2025年1-6月，上生公司净利润为23万元、-72万元，仅占公司净利润的 0.01%、-0.08%。（上述2025年1-6月数据未经审计） 本次董事会审议事项仅为上生公司处置项目立项，具体处置方案尚未确定，后续公司尚需按照相关规定 完成审计、评估等工作，确定处置方案，履行董事会审批程序，并及时进行信息披露。上生公司处置项 目具体实施方案及审批尚存在不确定性，敬请投资者注意投资风险。 特此公告。 证券代码：600161 证券简称：天坛生物 公告编号：2025-046 北京天坛生物制品股份有限公司 第九届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司(以下简称"公司")第九届董事会第二十五次会议于2025年9月19日以电 子方式发出会议通知，于2 ...

截至发稿，天坛生物市值为376亿元。 每经头条（nbdtoutiao）——5年增长33倍，这类新险种卖爆了，身边很多人都需要，30多家险企蜂拥而 入⋯⋯ （记者 张喜威） 每经AI快讯，天坛生物（SH 600161，收盘价：19.02元）9月26日晚间发布公告称，公司第九届第二十 五次董事会会议于2025年9月26日以通讯表决方式召开。会议审议了《关于处置上海上生生物制品经营 有限公司项目立项的议案》等文件。 2025年1至6月份，天坛生物的营业收入构成为：生物制品行业占比99.68%，其他业务占比0.32%。 ...

2024年，中国狂犬病发病数报告170例，较历史高峰下降超过95%。随着宠物防疫管理的加强，狂犬病发病人数降低，疫苗使用量却不减反增——每年， 中国消耗全球八成的人用狂犬病疫苗，我们真的需要接种如此大量的疫苗吗？ "宁可错打，不可放过"的临床原则背后，是狂犬病几乎100%的致死率和潜伏期难以检测。多数暴露案例会被建议按最严格的Ⅲ级处置接种疫苗，甚至加 注免疫球蛋白。随之而来的是经济负担的加重，全程接种费用已可轻松破千。这是否令部分真正的高风险人群因价格望而却步？ 当药企纷纷入局、市场竞争加剧的同时，动物源头的防控却始终薄弱，尤其是那些流浪犬、散养犬，成为病毒防疫链中最薄弱的一环。这狂犬疫苗，究竟 该给谁打？ 每年有多少人打狂犬疫苗？ 医院的狂犬病门诊外，总有人徘徊不定。他们前一秒可能还在与自家小狗亲密玩耍，后一秒却因一道轻微的破皮，不得不在昂贵的疫苗，与可能的100% 致死率之间做抉择。最终，大多数人还是会走进诊室。 中国人每年消耗全球80%以上的人用狂犬病疫苗——签发数超过5000万支，接种人数在1000万以上。中国人用狂犬病疫苗市场从2016年的30亿元增加至 2021年的53亿元，有咨询机构预计到202 ...

Market Overview - On September 26, the biopharmaceutical sector declined by 0.95%, with Junshi Bioscience leading the drop [1] - The Shanghai Composite Index closed at 3828.11, down 0.65%, while the Shenzhen Component Index closed at 13209.0, down 1.76% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopumai (688293) with a closing price of 66.17, up 5.28% [1] - Kanghua Biological (300841) at 77.28, up 5.26% [1] - Changchun High-tech (000661) at 126.89, up 3.53% [1] - Significant decliners included: - Junshi Bioscience (688180) at 41.00, down 4.16% [2] - Olin Bio (688319) at 25.50, down 3.66% [2] - Baipusais (301080) at 59.90, down 3.64% [2] Capital Flow - The biopharmaceutical sector experienced a net outflow of 412 million yuan from institutional investors, while retail investors saw a net inflow of 205 million yuan [2] - The capital flow for specific stocks showed: - Aopumai had a net inflow of 26.26 million yuan from institutional investors [3] - Kanghua Biological had a net outflow of 1.11 million yuan from retail investors [3] - Tonghua Dongbao (600867) saw a net inflow of 15.15 million yuan from institutional investors [3]

Group 1 - The core point of the article is that Xianfeng Holdings announced its total guarantee amount and the composition of its revenue for the first half of 2025, highlighting its financial stability and business segments [1] Group 2 - As of the announcement, the total guarantee amount provided by the company and its subsidiaries is 140 million yuan, which accounts for 17.07% of the latest audited net assets [1] - The total balance of guarantees provided to off-balance sheet entities is 20 million yuan, representing 2.44% of the latest audited net assets [1] - The company and its subsidiaries have no overdue guarantees, litigation-related guarantees, or guarantees due to adverse judgments [1] Group 3 - For the first half of 2025, the revenue composition of Xianfeng Holdings is as follows: electronic materials account for 57.48%, feed accounts for 35.4%, other products account for 3.92%, and bioproducts account for 3.2% [1] - The current market capitalization of Xianfeng Holdings is 3.9 billion yuan [1]

9月25日，赛伦生物跌0.99%，成交额1798.56万元。两融数据显示，当日赛伦生物获融资买入额149.58 万元，融资偿还208.08万元，融资净买入-58.50万元。截至9月25日，赛伦生物融资融券余额合计1.55亿 元。 融资方面，赛伦生物当日融资买入149.58万元。当前融资余额1.55亿元，占流通市值的6.19%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，赛伦生物9月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，上海赛伦生物技术股份有限公司位于上海市青浦区华青路1288号，成立日期1999年11月9 日，上市日期2022年3月11日，公司主营业务涉及研究、开发、生产及销售针对生物毒素及生物安全领 域的预防和治疗药物。主营业务收入构成为：抗血清抗毒素100.00%。 截至6月30日，赛伦生物股东户数7724.00，较上期增加9.39%；人均流通股5744股，较上期减少8.58%。 2025年1月-6月，赛伦生物实现营业收入1.01亿元，同比增长2.82%；归 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

Core Viewpoint - The clinical study of "Fusarium solani prick solution" developed by the company has successfully completed a Phase I clinical trial in Chinese volunteers, demonstrating good safety and effectiveness within the specified dosage range [1] Group 1: Clinical Study Results - The "Fusarium solani prick solution" showed good safety within the dosage range of 55DU/mL to 495000DU/mL, with adverse events being classified as Grade 1 or 2, and no serious adverse reactions or events leading to withdrawal [1] - A certain proportion of delayed reactions were observed among the subjects, potentially related to the fungal nature of Fusarium [1] - The specificity of the product at all dosages was over 95%, with no dose-related effects observed; sensitivity increased with dosage, reaching 95% at a dosage of 55000DU/mL [1] Group 2: Recommendations for Future Research - Researchers recommend advancing the product to subsequent clinical studies using dosages of 55000DU/mL and above, based on the review requirements of other marketed allergen prick solutions [1] - It is suggested to explore better solutions to reduce delayed reactions from a pharmaceutical perspective before conducting further preclinical studies [1]